非小细胞肺癌PD-L1表达异质性:活检标本与全切片的一致性判定标准
该研究以268例非小细胞肺癌构建组织微阵列模拟活检(每例5条芯针),比较SP263克隆PD-L1染色与全肿瘤切片结果。1%和50%截断值下总体阳性率分别为39%和10%,取芯针最大值与全切片一致性最高、假阴性最少。与全切片高一致需在1%和50%截断值下分别取4条和3条芯针;芯针以20%为截断值时,少于3条芯针识别全切片≥50%阳性的敏感性和特异性均高。
要点
- 芯针活检取最大值与全切片PD-L1一致性最高且假阴性最少。
- 1%和50%截断值下分别需4条和3条芯针才能与全切片高一致。
- 芯针20%–49%时,全切片≥50%阳性的概率1条为46%、2条为24%。
核心结论
- 准确界定判定PD-L1状态的标准有助于筛选可能从抗PD-1/PD-L1治疗中获益的患者。
研究设计与样本
- 研究纳入268例非小细胞肺癌,每例取5条芯针构建组织微阵列作为活检替代,采用经验证的SP263克隆行PD-L1染色并与全肿瘤切片比较。
主要发现
- 1%截断值下总体阳性率为39%,50%截断值下为10%。
- 取芯针最大值与全切片一致性高且总体假阴性病例数最低。
- 与全切片达高一致在1%和50%截断值下分别需4条和3条芯针。
- 芯针以20%为截断值时,少于3条芯针识别全切片≥50%PD-L1阳性肿瘤细胞的敏感性和特异性均高。
- 芯针PD-L1表达20%–49%时,全切片≥50%肿瘤细胞阳性的概率1条活检为46%、2条为24%。
关键数值与推荐
- 与全切片高一致的芯针条数:1%截断值需4条,50%截断值需3条。
- 芯针20%截断值下,少于3条芯针识别全切片≥50%阳性的敏感性和特异性均高。
- 芯针20%–49%时全切片≥50%阳性的概率:1条活检46%,2条活检24%。
临床怎么用
- 活检评估PD-L1时应综合多条芯针并取最大值,以减少假阴性。
- 需与全切片高一致时,1%和50%截断值下应分别取足4条和3条芯针。
- 芯针结果为20%–49%时需警惕全切片可能≥50%,必要时增加取样。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Determination of programmed death ligand 1 (PD-L1) expression defines eligibility for treatment with pembrolizumab in patients with advanced NSCLC. This study was designed to better define which value across core biopsy specimens from the same case more closely reflects the PD-L1 expression status on whole sections and how many core biopsy specimens are needed for confident classification of tumors in terms of PD-L1 expression. METHODS: We built tissue microarrays as surrogates of biopsies collecting five cores per case from 268 cases and compared PD-L1 staining results obtained by using the validated clone SP263 with the results obtained by using whole tumor sections. RESULTS: We found an overall positivity in 39% of cases at a cutoff of 1% and in 10% of cases at a cutoff of 50%. The maximum value across cores was associated with high concordance between cores and whole sections and the lowest number of false-negative cases overall. To reach high concordance with whole sections, four and three cores are necessary at cutoffs of 1% and 50%, respectively. Importantly, with 20% as the cutoff for core biopsy specimens, fewer than three cores showed high sensitivity and specificity in identifying cases with 50% or more of tumor cells positive for PD-L1 on whole sections. Specifically, for PD-L1 expression values of 20% to 49% on cores, the probabilities of a tumor specimen expressing PD-L1 in at least 50% of cells on a whole section were 46% and 24% with one and two biopsy specimens, respectively. CONCLUSIONS: An accurate definition of the criteria to determine the PD-L1 status of a given tumor may greatly help in selecting those patients who could benefit from anti-programmed cell death 1/PD-L1 treatment.
引用
- Munari E, Zamboni G, Lunardi G, et al. PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. J Thorac Oncol. 2018. PMID: 29704674. doi:10.1016/j.jtho.2018.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。